<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995653</url>
  </required_header>
  <id_info>
    <org_study_id>SER-155-001</org_study_id>
    <nct_id>NCT04995653</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT</brief_title>
  <official_title>A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation (HSCT) to Reduce the Risk of Infection and Graft vs. Host Disease (GvHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seres Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seres Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate&#xD;
      Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing&#xD;
      Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host&#xD;
      Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b randomized, double-blind, placebo-controlled, multiple dose, multicenter&#xD;
      study designed to evaluate the efficacy, safety and microbiome alterations associated with&#xD;
      SER-155 dosing, after pre-treatment with vancomycin, in adult subjects older than 18 years&#xD;
      who are undergoing Hematopoietic Stem Cell Transplantation (HSCT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>There are 2 parts or cohorts for the trial. Cohort 1 is an open-label study. Cohort 2 is double-blind, randomized, placebo-controlled study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the proportion of participants with an adverse events, serious adverse events, or adverse events of special interest through Day 100 after SER-155</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess engraftment: prevalence of SER-155 strains in subject stool measured before and after treatment courses through Day 100 with SER-155</measure>
    <time_frame>Day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the individual incidence of the bloodstream infections among recipients of SER-155 compared to placebo</measure>
    <time_frame>Day 100</time_frame>
    <description>AEs assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the individual incidence of the gastrointestinal infections among recipients of SER-155 compared to placebo</measure>
    <time_frame>Day 100</time_frame>
    <description>AEs assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the individual incidence of the Acute Graft-versus-Host Disease among recipients of SER-155 compared to placebo</measure>
    <time_frame>Day 100</time_frame>
    <description>AEs assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the individual incidence and duration of febrile neutropenia</measure>
    <time_frame>Day 365</time_frame>
    <description>AEs assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate overall survival among recipients of SER-155 compared to placebo</measure>
    <time_frame>Day 365</time_frame>
    <description>Overall survival is defined from the date of first vancomycin/SER-155 dose to death or censored at last clinical evaluation. OS estimated using the Kaplan-Meier method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Open Label Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin &amp; SER-155</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin &amp; SER-155 OR Vancomycin placebo &amp; SER-155 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Pre-Treatment</intervention_name>
    <description>Four times daily dosing with Vancomycin</description>
    <arm_group_label>Cohort 1 - Open Label Study</arm_group_label>
    <arm_group_label>Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Placebo</intervention_name>
    <description>Four times daily dosing with Vancomycin Placebo</description>
    <arm_group_label>Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER-155</intervention_name>
    <description>Once daily dosing with SER-155</description>
    <arm_group_label>Cohort 1 - Open Label Study</arm_group_label>
    <arm_group_label>Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER-155 Placebo</intervention_name>
    <description>Once daily dosing with SER-155 placebo</description>
    <arm_group_label>Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male and female subjects â‰¥ 18 years of age undergoing HSCT.&#xD;
&#xD;
        Planning to undergo allogeneic hematopoietic stem cell transplantation from a human&#xD;
        leukocyte antigen matched sibling, haploidentical related donor, or HLA-matched unrelated&#xD;
        donor with either bone marrow or peripheral blood stem cells as a graft source, and with&#xD;
        any conditioning regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Has severe colitis of any etiology or active/currently-treated inflammatory bowel disease&#xD;
        (IBD) or total colectomy.&#xD;
&#xD;
        Evidence of relapse or progression of hematologic malignancy (minimal residual disease is&#xD;
        allowed).&#xD;
&#xD;
        Transplant using umbilical cord blood or ex vivo T-cell-depleted HSCT&#xD;
&#xD;
        Receipt of chimeric antigen receptor T-cell (CAR-T) therapy.&#xD;
&#xD;
        Received a fecal microbiota transplant (FMT) or any live microbial therapeutic within 3&#xD;
        months prior to Screening.&#xD;
&#xD;
        Known allergy or intolerance to oral vancomycin.&#xD;
&#xD;
        Concomitant participation or participation within 1 month or 5 half-lives of another&#xD;
        investigational treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris Ponce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MSKCC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bina Tejura, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seres Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bina Tejura, MD</last_name>
    <phone>617-945-9626</phone>
    <email>clinicalstudies@serestherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Ponce, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>stem cell transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

